Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Inmagene Says IL-17A Shows Strong Efficacy for Chronic Skin Disease

publication date: Mar 20, 2023

Shanghai Inmagene Biopharma reported positive topline 12-week data from a US Phase IIb/III trial of its lead drug in patients with moderate-to-severe Hidradenitis Suppurativa. Izokibep is a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. In 2020, Inmagene, a company dedicated to developing therapies for immune-related diseases, acquired greater China rights to the candidate from Sweden's Affibody AB. HS is a chronic inflammatory skin disease that causes scarring, abscesses, malodor and pain, usually in areas close to sweat glands. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital